The Chengdu Municipal Bureau of Economic and Information Technology has unveiled a draft proposal titled “Several Policy Measures for Promoting High Quality Development of Biomedical Industry in Chengdu City” and is soliciting public feedback until November 15, 2024. The comprehensive document outlines 32 specific measures aimed at bolstering the biomedical industry in Chengdu, covering a wide range of areas from research and development to clinical applications and financing support.
The draft proposes substantial funding subsidies or rewards for the R&D of innovative drugs, modified drugs, and high-grade medical devices, with amounts ranging from RMB 500,000 to RMB 30 million. It emphasizes the government’s role in fostering collaborative innovation, enhancing CRO services, and streamlining the review and approval processes.
In terms of improving clinical research quality and efficiency, the document highlights initiatives to promote mutual recognition of medical ethics reviews and to bolster clinical research support systems. It also includes incentives for medical institutions that conduct clinical research and achieve Good Clinical Practice (GCP) accreditation.
Support for the clinical application of products includes measures to expedite hospital access to innovative medical devices, establish a catalog for such devices, and provide subsidies based on procurement amount of medical institutions. The draft also proposes opening a “green channel” for major innovative projects that enhance diagnosis and treatment plans and explore medical insurance payment support mechanisms.
For the development and growth of enterprises, the draft offers rewards for leading enterprises and those creating flagship products, with amounts ranging from RMB 300,000 to RMB 5 million. It also includes provisions to support enterprises in expanding into international markets and to reward those that industrialize innovative drugs and devices in Chengdu.
Investment and financing support is strengthen through improved funding systems and reduced credit costs for biopharmaceutical enterprises. The draft also emphasizes the creation of a robust industrial ecosystem by facilitating customs clearance for biomedicine special items, strengthening talent security, promoting intellectual property trading services, and ensuring the security of industrial land.
These measures, set to be valid for five years from the implementation date, are exclusive with other municipal supporting policies in Chengdu, signifying a focused effort to bolster the city’s biomedical industry.- Flcube.com
